Results 131 to 140 of about 60,909 (346)
Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer's disease, mild cognitive impairment, and healthy individuals [PDF]
, 2016 PURPOSE: The goal of this study is to investigate putative molecular dynamic changes in cerebrospinal fluids (CSFs) collected from individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD) as compared to healthy controls ...
Asthana, S +6 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 809-818, April 2025.Abstract Aims This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light‐chain amyloidosis (AL) and hereditary (ATTRv) and wild‐type transthyretin amyloidosis (ATTRwt)].
Alessia Argirò +20 more
wiley +1 more source
Tafamidis for the Treatment of Transthyretin Amyloidosis [PDF]
Future Cardiology, 2019 Transthyretin (TTR) related cardiomyopathy is an underdiagnosed cause of heart failure but is increasingly recognized in various settings - from patients admitted with heart failure to symptomatic aortic stenosis - and is rapidly becoming the most frequent form of systemic amyloidosis.
Massimiliano Lorenzini +2 more
openaire +3 more sources
Fish and amphibians as test organisms for evaluation of effects caused by chemicals [PDF]
, 2007 A large number of chemicals can contaminate aquatic environments and therefore be exposed to fish and amphibians during their sensitive stages of development.
Carlsson, Gunnar
core
Transthyretin is a metallopeptidase with an inducible active site [PDF]
, 2012 TTR (transthyretin) was found recently to possess proteolytic competency besides its well-known transport capabilities. It was described as a cryptic serine peptidase cleaving multiple natural substrates (including beta-amyloid and apolipoprotein A-I ...
Bur, Daniel +6 more
core +2 more sources
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
Circulation, 2020 Supplemental Digital Content is available in the text. Background: In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces all-cause mortality and cardiovascular hospitalizations and slows decline in quality of life compared with placebo.
Dhruv S. Kazi +10 more
semanticscholar +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Transthyretin is a promising prognostic marker of non-developing pregnancy in hypothyroidism
Фундаментальная и клиническая медицинаNon-developing pregnancy is one of the most important problems in the practice of an obstetrician-gynecologist. Transthyretin is a transplacental transport protein of T3, T4 and is expressed in cyto- and syncytiotrophoblast cells.
A. A. Orazmuradov +5 more
doaj +1 more source
Single-centre experience on transthyretin familial amyloid polyneuropathy : case series and literature review [PDF]
, 2018 Familial amyloid polyneuropathy (FAP) is a most often length-dependent axonal neuropathy, often part of a multisystem disorder also affecting other organs, such as cardiac, gastrointestinal, genitourinary, renal, meningeal and eye tissue.
De Bleecker, Jan +2 more
core +2 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy +15 more
wiley +1 more source